1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: The adoption or termination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers and directors for the three months ended September 30, 2025, each of which is intended to satisfy the affirmative defense of Rule 10b5-1(c) (Rule 10b5-1 Plan), were as follows:
−Removed: Rule 10b5-1 Trading Plan
−Removed: Aggregate # of
−Removed: Securities to be
−Removed: Expiration Date
−Removed: Purchase/Sale
−Removed: Purchased/Sold (a)
−Removed: Mitchell Chan
−Removed: Chief Financial Officer
−Removed: (a) The aggregate number of shares in this column includes shares that may be forfeited or withheld to satisfy exercise price and/or tax withholding obligations at the time of vesting.
−Removed: Other than as described above, during the three months ended September 30, 2025, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
+Added: During the three months ended March 31, 2026, no ne of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K).
Incorporated by Reference
1 unchanged sentence
Amended and Restated Bylaws
−Removed: First Amendment to Collaboration and License Agreement dated September 10, 2021 between the Registrant and AbbVie Global Enterprises Ltd.
+Added: Settlement and Release Agreement dated March 18, 2026 between the Registrant and GlaxoSmithKline LLC
+Added: License Agreement dated August 16, 2018 between the Registrant and Emory University
Certification of the Chief Executive Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002
1 unchanged sentence
Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C.
−Removed: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (eXtensible Business Reporting Language):
(i) Consolidated Balance Sheets
−Removed: (ii) Consolidated Statements of Operations and Comprehensive Loss
+Added: (ii) Consolidated Statements of Operations and Comprehensive Income (Loss)
(iii) Consolidated Statements of Stockholders’ Equity
1 unchanged sentence
(v) Notes to Consolidated Financial Statements
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 formatted in Inline XBRL (included in Exhibit 101)
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 formatted in Inline XBRL (included in Exhibit 101)
Portions of this exhibit have been omitted.
3 unchanged sentences
REGENXBIO Inc.
−Removed: November 6, 2025
/s/ Curran Simpson
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 6, 2025
/s/ Mitchell Chan
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.